Akebia Therapeutics annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Akebia Therapeutics Revenue Growth & History (AKBA)
Akebia Therapeutics reported $236.2M in revenue for fiscal 2025, an increase of 47.46% from the previous fiscal year.
View full Akebia Therapeutics company overviewAkebia Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $236.2M | $76.0M | +47.46% |
| 2024 | 2024-12-31 | $160.2M | −$34.4M | −17.70% |
| 2023 | 2023-12-31 | $194.6M | −$97.9M | −33.46% |
| 2022 | 2022-12-31 | $292.5M | $80.8M | +38.19% |
| 2021 | 2021-12-31 | $211.7M | −$83.0M | −28.17% |
| 2020 | 2020-12-31 | $294.6M | −$40.4M | −12.05% |
| 2019 | 2019-12-31 | $335.0M | $127.3M | +61.26% |
| 2018 | 2018-12-31 | $207.7M | $26.5M | +14.63% |
| 2017 | 2017-12-31 | $181.2M | $179.7M | +11706.32% |
| 2016 | 2016-12-31 | $1.5M | $1.5M | — |
| 2015 | 2015-12-31 | $0 | $0 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Akebia Therapeutics quarterly revenue
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $49.1M | −$13.3M | −21.36% |
| Q1 2026 | 2026-03-31 | $53.5M | −$3.8M | −6.61% |
| Q4 2025 | 2025-12-31 | $57.6M | $11.1M | +23.93% |
| Q3 2025 | 2025-09-30 | $58.8M | $21.3M | +57.01% |
| Q2 2025 | 2025-06-30 | $62.5M | $18.8M | +43.13% |
| Q1 2025 | 2025-03-31 | $57.3M | $24.7M | +75.84% |
| Q4 2024 | 2024-12-31 | $46.5M | −$9.7M | −17.26% |
| Q3 2024 | 2024-09-30 | $37.4M | −$4.6M | −10.98% |
| Q2 2024 | 2024-06-30 | $43.6M | −$12.7M | −22.58% |
| Q1 2024 | 2024-03-31 | $32.6M | −$7.4M | −18.49% |
| Q4 2023 | 2023-12-31 | $56.2M | $490,000 | +0.88% |
| Q3 2023 | 2023-09-30 | $42.0M | −$6.7M | −13.69% |
| Q2 2023 | 2023-06-30 | $56.4M | −$70.0M | −55.39% |
| Q1 2023 | 2023-03-31 | $40.0M | −$21.7M | −35.16% |
| Q4 2022 | 2022-12-31 | $55.7M | −$2.0M | −3.42% |
| Q3 2022 | 2022-09-30 | $48.7M | −$42,000 | −0.09% |
| Q2 2022 | 2022-06-30 | $126.4M | $73.5M | +138.82% |
| Q1 2022 | 2022-03-31 | $61.7M | $9.4M | +17.96% |
| Q4 2021 | 2021-12-31 | $57.7M | $1.6M | +2.93% |
| Q3 2021 | 2021-09-30 | $48.8M | −$11.2M | −18.72% |
| Q2 2021 | 2021-06-30 | $52.9M | −$37.2M | −41.30% |
| Q1 2021 | 2021-03-31 | $52.3M | −$36.2M | −40.88% |
| Q4 2020 | 2020-12-31 | $56.0M | −$13.5M | −19.44% |
| Q3 2020 | 2020-09-30 | $60.0M | −$32.0M | −34.78% |
| Q2 2020 | 2020-06-30 | $90.1M | −$10.7M | −10.58% |
| Q1 2020 | 2020-03-31 | $88.5M | $15.8M | +21.76% |
| Q4 2019 | 2019-12-31 | $69.6M | $9.7M | +16.22% |
| Q3 2019 | 2019-09-30 | $92.0M | $38.8M | +72.99% |
| Q2 2019 | 2019-06-30 | $100.8M | $52.0M | +106.59% |
| Q1 2019 | 2019-03-31 | $72.7M | $26.7M | +58.21% |
| Q4 2018 | 2018-12-31 | $59.9M | — | — |
| Q3 2018 | 2018-09-30 | $53.2M | $11.9M | +28.79% |
| Q2 2018 | 2018-06-30 | $48.8M | $20.3M | +71.08% |
| Q1 2018 | 2018-03-31 | $45.9M | — | — |
| Q3 2017 | 2017-09-30 | $41.3M | $41.3M | — |
| Q2 2017 | 2017-06-30 | $28.5M | $28.5M | — |
| Q4 2016 | 2016-12-31 | $1.5M | $1.5M | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $0 | $0 | — |
| Q1 2016 | 2016-03-31 | $0 | $0 | — |
| Q4 2015 | 2015-12-31 | $0 | — | — |
| Q3 2015 | 2015-09-30 | $0 | — | — |
| Q2 2015 | 2015-06-30 | $0 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Akebia Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $294.6M to $236.2M, a compound annual decline of 4.33%. Akebia Therapeutics's latest reported quarter, Q2 2026, generated $49.1M in revenue, a decrease of 21.36% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Akebia Therapeutics source filings ↗Community posts
Akebia doses the first patient in a rare-kidney-disease trial
Akebia ($AKBA) Therapeutics dosed the first patient in its Phase 2 basket trial of ebribafusp, an experimental treatment for rare complement-mediated kidney diseases. The study covers IgA nephropathy, lupus nephritis and C3 glomerulopathy. ...
